<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687191</url>
  </required_header>
  <id_info>
    <org_study_id>B2341002</org_study_id>
    <secondary_id>2015-005703-83</secondary_id>
    <nct_id>NCT02687191</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage</brief_title>
  <official_title>A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study employs a modified continual reassessment method (mCRM) design to estimate the
      maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based
      on treatment emergent thromboembolic and/or ischemic events (TIEs). The mCRM design utilizes
      Bayesian methodology to continuously learn the dose-toxicity relationship, which is
      characterized by a parametric model.

      Subjects with a diagnosis of ICH (determined by computed tomography) will be enrolled in
      cohorts of 3. The total length of time planned for study participation is approximately 3
      months; 6.0 hours for screening, a single dose administration with a 4-day minimum hospital
      confinement period and follow-up visits through Day 91.

      Severity of adverse events (AEs) and serious adverse events (SAEs) will be graded according
      to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
      version 4.03. All subjects who receive PF-05230907 are evaluable for TIEs. The determination
      of MTD using mCRM modeling will be based on TIEs which occur through 7 days post-dose (Day
      8).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    B2341002 was terminated on 26-OCT-2017 for strategic reasons. The decision to terminate the
    trial was not based on any safety concerns.
  </why_stopped>
  <start_date type="Actual">November 26, 2016</start_date>
  <completion_date type="Actual">January 16, 2018</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment emergent thromboembolic and/or ischemic events (TIEs)</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment emergent serious adverse events (SAEs)</measure>
    <time_frame>Day 1 through Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment emergent adverse events (AEs)</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment emergent laboratory abnormalities</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Day 1 through Day 8 for D-dimer labs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination changes</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital sign changes</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) results</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in aPTT</measure>
    <time_frame>Day 1 through Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PF 1+2</measure>
    <time_frame>Day 1 through Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-drug and/or neutralizing antibody production</measure>
    <time_frame>Day 1 through Day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor X activity</measure>
    <time_frame>Day 1 through Day 91</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in ICH volume from baseline volume at 24 hours</measure>
    <time_frame>Day 1 to Day 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>PF-05230907 concentration in plasma</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of anti-Chinese hamster ovary (CHO) protein antibody production</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of anti-paired basic amino acid cleaving enzyme (PACE) furin antibody production</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neurological function as assessed by the NIH Stroke Scale</measure>
    <time_frame>Day 1 through Day 91</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Health resource utilization</measure>
    <time_frame>Day 8 through Day 91</time_frame>
  </other_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 13)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 14)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05230907 (Cohort 15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05230907 IV bolus injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>PF-05230907 IV bolus injection</description>
    <arm_group_label>PF-05230907 (Cohort 1)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 2)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 3)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 4)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 5)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 6)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 7)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 8)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 9)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 10)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 11)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 12)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 13)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 14)</arm_group_label>
    <arm_group_label>PF-05230907 (Cohort 15)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICH as documented by CT scan within 6.0 hours of symptom onset

          -  Baseline ICH volume &gt; 5mL and &lt; 60 mL

        Exclusion Criteria:

          -  Deep coma (Glasgow Coma Scale &lt; 6)

          -  Modified Rankin Score &gt; 3 prior to ICH onset

          -  Known history of schemic, vaso-occlusive or thrombotic events within 6 months prior to
             screening

          -  Known prothrombotic disorders

          -  Known secondary ICH related to aneurysm, arteriovenous malformation, subarachnoid
             hemorrhage, trauma, or other causes. CT angiography, MR, or other diagnostic studies
             obtained as part of the standard of care may be used to assess eligibility.

          -  Known use of oral anticoagulant(s)

          -  Known use of low-molecular weight heparin or heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University,</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martha Morehouse Medical Plaza</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela, Area Neurovascular-Neurologia</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron, Unidad de Ictus</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta IDIBGI, Department Neurology</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2341002&amp;StudyName=A%20Phase%201b%20Multicenter%2C%20Open-label%20Study%20To%20Evaluate%20The%20Safety%20And%20Tolerability%20To%20Determine%20The%20Maximum%20Tolerated%20Dose%20Of%20Pf-05230907%20In%20Intracerebral%20Hemorrhage%20%28ich%29%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2341002&amp;StudyName=A+Phase+1b+Multicenter%2C+Open-label+Study+To+Evaluate+The+Safety+And+Tolerability+And+Determine+The+Maximum+Tolerated+Dose+Of+Pf-05230907+In+Subjects+With+Intracerebral+Hemorrhage+%28ich%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety, maximum tolerated dose, modified continual reassessment method, intracerebral, hemorrhage, hematoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

